PCNA and cancer: Studies have shown that the combination of APIM-peptide and cisplatin alters the expression of proteins involved in cancer cell growth and cisplatin resistance, reduces the expression of genes related to the DNA damage response, and likely inhibits key pathways dependent on PCNA interactions [246].